TCMD Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

93.80M

+9.6%

0.440

+10%

68.46M

+11.74%

-0.090

-30.77%

86.48M

+9.6%

0.190

+35.71%

Estimates Revision

The market is revising Upward the revenue expectations for Tactile Systems Technology, Inc. (TCMD) for FY2025, with the revenue forecasts being adjusted by 2.59% over the past three months. During the same period, the stock price has changed by 112.66%.

Revenue Estimates for FY2025

Revise Upward

+2.59%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+29.76%

In Past 3 Month

Stock Price

Go Up

+112.66%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast TCMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TCMD is 26.67 USD with a low forecast of 20.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

20.00

Averages

26.67

High

32.00

Current: 0.000

Low

20.00

Averages

26.67

High

32.00

Piper Sandler

Adam Maeder

Neutral -> Overweight

upgrade

$20 -> $35

2026-01-05

New

Reason

Piper Sandler

Adam Maeder

Price Target

$20 -> $35

2026-01-05

New

upgrade

Neutral -> Overweight

Reason

Piper Sandler analyst Adam Maeder upgraded Tactile Systems to Overweight from Neutral with a price target of $35, up from $20.

Piper Sandler

Adam Maeder

Neutral -> Overweight

upgrade

$20 -> $35

2026-01-05

New

Reason

Piper Sandler

Adam Maeder

Price Target

$20 -> $35

2026-01-05

New

upgrade

Neutral -> Overweight

Reason

As previously reported, Piper Sandler analyst Adam Maeder upgraded Tactile Systems to Overweight from Neutral with a price target of $35, up from $20. The firm notes the lymphedema business appears to have stabilized and has a couple of catalysts on-the-come; Afflovest has consistently outperformed expectations in 2025 year-to-date and it sees plenty of growth runway going forward; valuation screens positive despite the run in the stock over the past 6 months; and Piper thought management gave a bullish update at the 2025 Piper Sandler Healthcare Conference. Looking ahead, the firm sees a potential pathway back to double-digit growth in FY26 and beyond. Piper combines this level of expected top-line growth with net income profitability, and it sees a favorable risk-reward.

Lake Street

Buy

maintain

$32

2025-11-04

Reason

Lake Street

Price Target

$32

2025-11-04

maintain

Buy

Reason

Lake Street raised the firm's price target on Tactile Systems to $32 from $23.50 and keeps a Buy rating on the shares after "a massive Q3 outperformance" that included the company more than doubling the firm's EPS estimate and exceeding its revenue forecast by nearly 9%. The firm anticipates a return to double-digit top line growth in FY26, the analyst tells investors in a post-earnings note.

Piper Sandler

Neutral

maintain

$14 -> $20

2025-11-04

Reason

Piper Sandler

Price Target

$14 -> $20

2025-11-04

maintain

Neutral

Reason

Piper Sandler raised the firm's price target on Tactile Systems to $20 from $14 and keeps a Neutral rating on the shares. The firm notes the company posted Q3 top-line results that beat estimates, driven by good performance in both the Lymphedema and AffloVest businesses. Tactile increased its full year 2025 guidance by $6.5M at the midpoint to $317M-$321M as strength in the AffloVest business is expected to continue and as the lymphedema business is benefiting from increased productivity from a larger sales force. However, Piper wrestles with some of the visibility into the ongoing trends in this business after two consecutive guide downs to start the year.

BTIG

Neutral -> Buy

upgrade

$28

2025-11-04

Reason

BTIG

Price Target

$28

2025-11-04

upgrade

Neutral -> Buy

Reason

BTIG upgraded Tactile Systems to Buy from Neutral with a $28 price target. The firm views the company's Q3 results as "very encouraging." Tactile beat expectations for the second straight quarter and is generating improved performance from productivity enhancements, sales force expansion, new products, and improved reimbursement dynamics, the analyst tells investors in a research note. BTIG believes the shares are now setup well for the next 12-24 months and can support a higher multiple. Tactile Systems "is in the midst of a turnaround" and it is time to come off the sidelines again, contends the firm.

B. Riley

Anderson Schock

Neutral

maintain

$12 -> $13

2025-08-05

Reason

B. Riley

Anderson Schock

Price Target

$12 -> $13

2025-08-05

maintain

Neutral

Reason

B. Riley analyst Anderson Schock raised the firm's price target on Tactile Systems to $13 from $12 and keeps a Neutral rating on the shares following the Q2 report. The firm cites the company's raised guidance and reduced share count for the target bump.

Valuation Metrics

The current forward P/E ratio for Tactile Systems Technology Inc (TCMD.O) is 30.11, compared to its 5-year average forward P/E of 98.83. For a more detailed relative valuation and DCF analysis to assess Tactile Systems Technology Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

98.83

Current PE

30.11

Overvalued PE

590.38

Undervalued PE

-392.72

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

17.18

Current EV/EBITDA

13.44

Overvalued EV/EBITDA

32.06

Undervalued EV/EBITDA

2.29

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

1.67

Current PS

1.80

Overvalued PS

2.92

Undervalued PS

0.42

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

TCMD News & Events

Events Timeline

No data

News

3.0

2025-11-28NASDAQ.COM

Tactile Systems Technology (TCMD) Shows Strong Growth Potential: Is It a Good Investment?

3.0

2025-11-20NASDAQ.COM

Zacks.com Spotlights Tactile Systems, Canadian Natural Resources, Arlo, and Celestica

4.0

2025-11-19NASDAQ.COM

Top Strong Buy Stocks for November 19: TCMD, NPSNY, and Others

People Also Watch

Frequently Asked Questions

What is Tactile Systems Technology Inc (TCMD) stock price today?

The current price of TCMD is 30.24 USD — it has decreased -1.59 % in the last trading day.

What is Tactile Systems Technology Inc (TCMD)'s business?

Tactile Systems Technology, Inc., doing business as Tactile Medical, is a medical technology company that manufactures and distributes medical devices for the treatment of patients with chronic diseases at home. The Company's areas of therapeutic focus are vascular disease, oncology and providing airway clearance therapy for those suffering from chronic respiratory conditions. It is developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. It markets Flexitouch Plus and Entre Plus systems as at-home therapies for the treatment of lymphedema and chronic venous insufficiency. It markets AffloVest as an at-home therapy intended to promote airway clearance. Its Flexitouch Plus system is a fully automated, programmable, advanced pneumatic compression device. It also offers Kylee, a free mobile application that helps patients learn about lymphedema.

What is the price predicton of TCMD Stock?

What is Tactile Systems Technology Inc (TCMD)'s revenue for the last quarter?

Tactile Systems Technology Inc revenue for the last quarter amounts to 85.76M USD, increased 17.32 % YoY.

What is Tactile Systems Technology Inc (TCMD)'s earnings per share (EPS) for the last quarter?

Tactile Systems Technology Inc. EPS for the last quarter amounts to 0.36 USD, increased 71.43 % YoY.

What changes have occurred in the market's expectations for Tactile Systems Technology Inc (TCMD)'s fundamentals?

How many employees does Tactile Systems Technology Inc (TCMD). have?

Tactile Systems Technology Inc (TCMD) has 1037 emplpoyees as of January 10 2026.

What is Tactile Systems Technology Inc (TCMD) market cap?

Today TCMD has the market capitalization of 675.43M USD.